BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...
BioAffinity Technologies shares declined after the company announced a $2.66 million registered direct offering of stock and a concurrent private placement of warrants. Shares were down 25%, to $1.59, ...
Results that may be inaccessible to you are currently showing.